scholarly journals Recent Progress in Vaccine Development Against Chikungunya Virus

2019 ◽  
Vol 10 ◽  
Author(s):  
Shan Gao ◽  
Siqi Song ◽  
Leiliang Zhang
Keyword(s):  
Chikungunya Virus ◽  
Recent Progress ◽  
Vaccine Development

scholarly journals Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape

2021 ◽  
Vol 9 (5) ◽  
pp. 899
Author(s):  
Anthony Torres-Ruesta ◽  
Rhonda Sin-Ling Chee ◽  
Lisa F.P. Ng
Keyword(s):  
Diagnostic Tests ◽  
Inflammatory Arthritis ◽  
Chikungunya Virus ◽  
Vaccine Development ◽  
Antibody Responses ◽  
Chikv Infection ◽  
Wide Range ◽  
Susceptible Populations ◽  
Humoral Responses

Alphaviruses are mosquito-borne pathogens distributed worldwide in tropical and temperate areas causing a wide range of symptoms ranging from inflammatory arthritis-like manifestations to the induction of encephalitis in humans. Historically, large outbreaks in susceptible populations have been recorded followed by the development of protective long-lasting antibody responses suggesting a potential advantageous role for a vaccine. Although the current understanding of alphavirus antibody-mediated immunity has been mainly gathered in natural and experimental settings of chikungunya virus (CHIKV) infection, little is known about the humoral responses triggered by other emerging alphaviruses. This knowledge is needed to improve serology-based diagnostic tests and the development of highly effective cross-protective vaccines. Here, we review the role of antibody-mediated immunity upon arthritogenic and neurotropic alphavirus infections, and the current research efforts for the development of vaccines as a tool to control future alphavirus outbreaks.

scholarly journals Mucosal Vaccine Development Based on Liposome Technology

2016 ◽  
Vol 2016 ◽  
pp. 1-16 ◽  
Author(s):  
Valentina Bernasconi ◽  
Karin Norling ◽  
Marta Bally ◽  
Fredrik Höök ◽  
Nils Y. Lycke
Keyword(s):  
Immune Responses ◽  
Protective Immunity ◽  
Recent Progress ◽  
Vaccine Development ◽  
Mucosal Vaccine ◽  
Limiting Factor ◽  
Successful Development ◽  
Mucosal Vaccines ◽  
Increasing Demand ◽  
Portal Of Entry

Immune protection against infectious diseases is most effective if located at the portal of entry of the pathogen. Hence, there is an increasing demand for vaccine formulations that can induce strong protective immunity following oral, respiratory, or genital tract administration. At present, only few mucosal vaccines are found on the market, but recent technological advancements and a better understanding of the principles that govern priming of mucosal immune responses have contributed to a more optimistic view on the future of mucosal vaccines. Compared to live attenuated vaccines, subcomponent vaccines, most often protein-based, are considered safer, more stable, and less complicated to manufacture, but they require the addition of nontoxic and clinically safe adjuvants to be effective. In addition, another limiting factor is the large antigen dose that usually is required for mucosal vaccines. Therefore, the combination of mucosal adjuvants with the recent progress in nanoparticle technology provides an attractive solution to these problems. In particular, the liposome technology is ideal for combining protein antigen and adjuvant into an effective mucosal vaccine. Here, we describe and discuss recent progress in nanoparticle formulations using various types of liposomes that convey strong promise for the successful development of the next generation of mucosal vaccines.

Recent progress in tumour vaccine development

2003 ◽  
Vol 12 (6) ◽  
pp. 971-981 ◽  
Author(s):  
I Caroline Le Poole ◽  
Hemamalini Bommiasamy ◽  
W Martin Kast
Keyword(s):  
Recent Progress ◽  
Vaccine Development ◽  
Tumour Vaccine

scholarly journals Recent progress on chikungunya virus research

2017 ◽  
Vol 32 (6) ◽  
pp. 441-453 ◽  
Author(s):  
Wenxi An ◽  
Ningning Ge ◽  
Yilin Cao ◽  
Jin Sun ◽  
Xia Jin
Keyword(s):  
Chikungunya Virus ◽  
Recent Progress ◽  
Virus Research

scholarly journals Towards a Systems Immunology Approach to Understanding Correlates of Protective Immunity against HCV

Viruses ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1871
Author(s):  
Naglaa H. Shoukry
Keyword(s):  
Systems Biology ◽  
Protective Immunity ◽  
Recent Progress ◽  
Viral Infections ◽  
Vaccine Development ◽  
Immune Functions ◽  
The Past ◽  
Systems Immunology ◽  
Tremendous Progress ◽  
Made In

Over the past decade, tremendous progress has been made in systems biology-based approaches to studying immunity to viral infections and responses to vaccines. These approaches that integrate multiple facets of the immune response, including transcriptomics, serology and immune functions, are now being applied to understand correlates of protective immunity against hepatitis C virus (HCV) infection and to inform vaccine development. This review focuses on recent progress in understanding immunity to HCV using systems biology, specifically transcriptomic and epigenetic studies. It also examines proposed strategies moving forward towards an integrated systems immunology approach for predicting and evaluating the efficacy of the next generation of HCV vaccines.

scholarly journals Diagnostic Options and Challenges for Dengue and Chikungunya Viruses

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Stacey K. Mardekian ◽  
Amity L. Roberts
Keyword(s):  
Drug Development ◽  
Antibody Response ◽  
Diagnostic Tests ◽  
Chikungunya Virus ◽  
Recent Progress ◽  
Management Strategies ◽  
Accurate Diagnosis ◽  
Mosquito Vectors ◽  
Clinical Presentations ◽  
Immune Antibody

Dengue virus (DENV) and Chikungunya virus (CHIKV) are arboviruses that share the sameAedesmosquito vectors and thus overlap in their endemic areas. These two viruses also cause similar clinical presentations, especially in the initial stages of infection, with neither virus possessing any specific distinguishing clinical features. Because the outcomes and management strategies for these two viruses are vastly different, early and accurate diagnosis is imperative. Diagnosis is also important for surveillance, outbreak control, and research related to vaccine and drug development. Available diagnostic tests are aimed at detection of the virus, its antigenic components, or the host immune antibody response. In this review, we describe the recent progress and continued challenges related to the diagnosis of DENV and CHIKV infections.

Recent progress in tumour vaccine development

2003 ◽  
Vol 12 (6) ◽  
pp. 971-981
Author(s):  
I Caroline Poole ◽  
Hemamalini Bommiasamy ◽  
W Martin Kast
Keyword(s):  
Recent Progress ◽  
Vaccine Development ◽  
Tumour Vaccine

Tuberculosis vaccine development: recent progress

2001 ◽  
Vol 9 (3) ◽  
pp. 115-118 ◽  
Author(s):  
Ian M. Orme ◽  
David N. McMurray ◽  
John T. Belisle
Keyword(s):  
Recent Progress ◽  
Vaccine Development
Sign in / Sign up

Export Citation Format

Share Document